CSII实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (28 Apr 2023 @ 04:00):

Cardiovascular Systems, Inc., a medical technology company, develops and commercializes solutions to treat peripheral and coronary artery diseases in the United States and internationally...

Stats
今日成交量	387 776
平均成交量	677 842
市值	843.96M
EPS	$0 ( 2024-02-07 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-20.83
ATR14	$0.103 (0.52%)

Insider Trading

Date	Person	Action	Amount	type
2023-04-27	Paulsen Erik	Sell	20 627	Restricted Stock Units
2023-04-27	Paulsen Erik	Sell	700	Common Stock
2023-04-27	Points Jeffrey S.	Sell	138 957	Common Stock
2023-04-27	Points Jeffrey S.	Sell	34 051	Common Stock
2023-04-27	Rempe Stephen J.	Sell	75 659	Common Stock

INSIDER POWER
-79.56
Last 100 transactions
Buy: 675 433 \| Sell: 1 911 221

音量相关性

長: 0.24 (neutral)

短: -0.52 (weak negative)

Signal:(76.086) Neutral

Cardiovascular Systems 相关性

10 最正相关
ATCX	0.992
MOR	0.983
TA	0.978
PNT	0.972
IIN	0.972
ECHO	0.968
SPRB	0.966
IFRX	0.963
LGMK	0.962
BUR	0.956

10 最负相关
SJ	-0.961
MDXH	-0.959
CHTR	-0.958
MRBK	-0.955
UTMD	-0.952
BIOL	-0.951
WTER	-0.95
BSET	-0.948
LBRDA	-0.945
ONCT	-0.944

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Cardiovascular Systems 相关性 - 货币/商品

0.77
( moderate )

0.53
( weak )

0.54
( weak )

0.46
( neutral )

-0.73
( moderate negative )

Cardiovascular Systems 财务报表

Annual	2022
营收:	$236.22M
毛利润:	$172.78M (73.14 %)
EPS:	$-0.940

FY	2022
营收:	$236.22M
毛利润:	$172.78M (73.14 %)
EPS:	$-0.940

FY	2021
营收:	$258.97M
毛利润:	$197.84M (76.39 %)
EPS:	$-0.350

FY	2020
营收:	$236.55M
毛利润:	$187.79M (79.39 %)
EPS:	$-0.790

Financial Reports:

No articles found.

Cardiovascular Systems

Cardiovascular Systems, Inc., a medical technology company, develops and commercializes solutions to treat peripheral and coronary artery diseases in the United States and internationally. The company offers peripheral artery disease products comprising catheter-based platforms to treat various plaque types in above and below the knee, including calcified plaque, as well as address various limitations related with surgical, catheter, and pharmacological treatment alternatives; and peripheral support products. It also provides Diamondback 360 Coronary orbital atherectomy systems (OAS), a coronary artery disease (CAD) product designed to facilitate stent delivery in patients with CAD who are acceptable candidates for percutaneous transluminal coronary angioplasty or stenting due to severely calcified coronary artery lesions. In addition, it offers guidewires, catheters, balloons, embolic protection system, and other OAS support products. Cardiovascular Systems, Inc. has a partnership with Chansu Vascular Technologies, LLC to develop novel peripheral and coronary everolimus drug-coated balloons. The company was formerly known as Shturman Cardiology Systems, Inc. and changed its name to Cardiovascular Systems, Inc. in January 2003. Cardiovascular Systems, Inc. was founded in 1989 and is headquartered in Saint Paul, Minnesota.